Presented at SDPA, the FOREMOST Trial showed apremilast reduces joint burden and improves function in early oligo PsA through week 48.
Society of Dermatology Physician Assistants
Advertisement
Advertisement
Trending on Rheumatology Live
1
Sonelokimab Reduces Inflammation, Osteoblastic Activity in Phase 2 Proof-of-Concept axSpA Study
2
Bimekizumab Beats Risankizumab on ACR50 in First IL-17A/F vs IL-23 Head-to-Head
3
Joint Ventures: CAR-T, Early Diagnosis Reshape Scleroderma at EULAR 2026
4
Nipocalimab Demonstrates Proof of Concept for FcRn Blockade for SLE
5